Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil/memantine extended release - Lyndra Therapeutics

Next Previous
Drug Profile

Donepezil/memantine extended release - Lyndra Therapeutics

Alternative Names: Donepezil HCl/memantine HCl extended release - Lyndra Therapeutics; LYN-157

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyndra
  • Class Analgesics; Antidementias; Antiparkinsonians; Antispastics; Indans; Nootropics; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Nicotinic antagonists; NMDA receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 28 May 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease in Australia (PO, Controlled release)
  • 14 Nov 2020 Lyndra Therapeutics initiates phase I trial in Alzheimer's Disease (In volunteers) in Australia (ACTRN12619001566123)
  • 27 Jul 2020 Pharmacokinetics and adverse event data from a phase I trial in Healthy volunteers presented at Alzheimer's Association International Conference 2020 (AAIC-2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top